

Review

# Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

Shalini Gupta <sup>a,\*</sup>, Stephen R. Indelicato <sup>b</sup>, Vijay Jethwa <sup>c</sup>, Thomas Kawabata <sup>d</sup>,  
Marian Kelley <sup>e</sup>, Anthony R. Mire-Sluis <sup>f</sup>, Susan M. Richards <sup>g</sup>, Bonita Rup <sup>h</sup>,  
Elizabeth Shores <sup>i,1</sup>, Steven J. Swanson <sup>a</sup>, Eric Wakshull <sup>j</sup>

<sup>a</sup> *Clinical Immunology, Amgen Inc., Thousand Oaks, CA 91320, USA*

<sup>b</sup> *PharmSci Quality-Quality Systems Improvement Office, Schering Plough Research Institute, Kenilworth, NJ, 07033, USA*

<sup>c</sup> *Bioanalytical QC RTP, Biogen Idec, Research Triangle Park, NC 27709, USA*

<sup>d</sup> *Safety Sciences, Pfizer Global Research and Development, Groton, CT 06340, USA*

<sup>e</sup> *Clinical Pharmacology & Experimental Medicine, Centocor R&D Inc., Radnor, PA 19087, USA*

<sup>f</sup> *Corporate Operations, Amgen Inc., Thousand Oaks, CA 91320, USA*

<sup>g</sup> *Immunology, Cell & Protein Therapeutics R&D, Genzyme Corp. Framingham, MA 01701, USA*

<sup>h</sup> *Bioanalytical R&D, Wyeth Research, Andover, MA 01810, USA*

<sup>i</sup> *Division of Therapeutic Protein, Office of Biotechnology Product, Center for Drug Evaluation and Research, FDA, MD 20892, USA*

<sup>j</sup> *Clinical Science & Technology, Biogen Idec, Cambridge, MA 02142, USA*

Received 4 April 2006; received in revised form 29 November 2006; accepted 6 December 2006

Available online 12 January 2007

## Abstract

The administration of biological therapeutics can evoke some level of immune response to the drug product in the receiving subjects. An immune response comprised of neutralizing antibodies can lead to loss of efficacy or potentially more serious clinical sequelae. Therefore, it is important to monitor the immunogenicity of biological therapeutics throughout the drug product development cycle. Immunoassays are typically used to screen for the presence and development of anti-drug product antibodies. However, in-vitro cell-based assays prove extremely useful for the characterization of immunoassay-positive samples to determine if the detected antibodies have neutralizing properties. This document provides scientific recommendations based on the experience of the authors for the development of cell-based assays for the detection of neutralizing antibodies in non-clinical and clinical studies. © 2006 Elsevier B.V. All rights reserved.

**Keywords:** Neutralizing antibody bioassay; Cell-based assay; Serum-based bioassay; Immunogenicity assay; NAb assay

**Abbreviations:** BrdU, bromodeoxyuridine; CAT, chloramphenicol acetyl transferase; CV, coefficient of variance; ECL, electrochemiluminescence; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; EPO, erythropoietin; FACS, flow activated cell sorting; GFP, Green Fluorescent Protein; HSA, human serum albumin; Ig, immunoglobulin; IL-1, interleukin-1; KIRA, kinase induced receptor activation; MAb, monoclonal antibody; MGDF, megakaryocyte growth and development factor; mRNA, messenger ribonucleic acid; MTT, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]; NAb, neutralizing antibody; RIA, radioimmunoassay; PRCA, pure red cell aplasia; rHuEPO, recombinant human EPO; SPA, scintillation proximity assay; TNF, tumor necrosis factor.

\* Corresponding author. Tel.: +1 805 447 1117; fax: +1 805 499 5842.

E-mail address: shalinig@amgen.com (S. Gupta).

<sup>1</sup> The views expressed herein reflect the opinions of the author and not necessarily those of the FDA.

## Contents

1.	Introduction . . . . .	2
2.	General principles for NAb assay design . . . . .	3
2.1.	Principle of a cell-based NAb assay . . . . .	3
2.2.	Impact of drug's mode of action on NAb assay design . . . . .	3
2.3.	Risk-based approach to cell-based NAb testing . . . . .	4
2.4.	Utility of matrix interference assays in NAb testing. . . . .	4
3.	Assay design: considerations and critical components . . . . .	4
3.1.	Selection of the cell line . . . . .	4
3.2.	Selection of the assay endpoint . . . . .	5
3.3.	Positive control antibody . . . . .	5
4.	Assay development: assay formats . . . . .	7
4.1.	Direct NAb assay . . . . .	7
4.2.	Indirect NAb assay . . . . .	7
4.3.	Qualitative NAb assay . . . . .	8
4.4.	Quasi-quantitative NAb assay . . . . .	8
4.5.	Matrix interference assays . . . . .	9
4.5.1.	Alternative stimulus assay . . . . .	9
4.5.2.	Sample-induced response assay. . . . .	11
4.5.3.	Immunodepletion assay. . . . .	11
4.5.4.	Immunocompetition assay . . . . .	11
5.	Assay optimization . . . . .	12
5.1.	Selection of drug product concentration . . . . .	12
5.1.1.	Direct NAb assay . . . . .	12
5.1.2.	Indirect NAb assay . . . . .	12
5.2.	Selection of sample matrix dilution . . . . .	13
5.3.	Assay response range . . . . .	13
5.4.	Assay robustness. . . . .	13
5.5.	Assay incubation conditions . . . . .	13
6.	Assay qualification . . . . .	13
6.1.	Characteristics of the drug product standard curve . . . . .	14
6.2.	Characteristics of the positive control antibody curve . . . . .	14
6.3.	Assay cut points for the NAb assay . . . . .	14
6.3.1.	Blank donor sera . . . . .	14
6.3.2.	Ratio of antibody spiked and blank donor sera (post to pre ratio) . . . . .	15
6.4.	Assay cut point for the matrix interference assay . . . . .	15
6.4.1.	Alternative stimulus assay . . . . .	15
6.4.2.	Sample-induced response . . . . .	15
6.5.	Assay sensitivity . . . . .	16
6.6.	Assay standardization . . . . .	16
7.	Conclusions . . . . .	16
	Acknowledgements . . . . .	17
	References . . . . .	17

## 1. Introduction

The development of antibodies to biological therapeutics upon their administration in study subjects is not an uncommon occurrence (Porter, 2000). On a case-by-case basis, the antibody response may be inconsequential or may have a dramatic effect on the efficacy and/or safety of the drug product if the antibodies alter drug pharmacokinetics or are of a neutralizing nature. Neutralizing anti-

bodies (NAbs) block the biological activity of the therapeutic molecule by either binding directly to epitope(s) that lie within the active site of the therapeutic molecule or by blocking its active site by steric hindrance due to binding to epitope(s) that may lie in close proximity to the active site. While, in certain cases NAb presence may not result in a clinical effect, at sufficient NAb levels in other cases, a decrease in efficacy may be observed which may require administration of higher doses of the

Download English Version:

<https://daneshyari.com/en/article/2089446>

Download Persian Version:

<https://daneshyari.com/article/2089446>

[Daneshyari.com](https://daneshyari.com)